News for Incyte Corporation (INCY)

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck for the India's largest pharmaceutical company to launch its alopecia drug Leqselvi in the United States.

Stocks including TCS, Tata Steel, GAIL (India), Infosys, BHEL, Sun Pharma, NBCC (India), Bharti Hexacom, Eternal, Aurobindo Pharma and TARC will be in the spotlight on Friday, April 10.

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions on the launch on April 9, Sun Pharma said in a regulatory filing.

Incyte (INCY) will announce its Q1 2025 financial results on April 29, 2025, at 7:00 a.m. ET. The company will hold a conference call and webcast at 8:0

Sun Pharmaceutical Industries Ltd on Thursday said a US court has ruled in its favour and vacated a preliminary injunction effective immediately removing restrictions on it launching LEQSELVI, a drug used to treat autoimmune disorder that causes patchy hair loss. Sun Pharma had been locked in a patent infringement litigation with Incyte Corporation over LEQSELVI (deuruxolitinib).

Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff.

Tariffs could heavily impact top tech beneficiaries of globalization as the cost of the goods sold by these firms may rise.

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced to…

On March 19, 2025, BB Biotech AG made a significant move by reducing its position in Black Diamond Therapeutics Inc (NASDAQ: BDTX). The firm sold 5,784,292 shar

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa. In each of the trials, the drug met its primary endpoint of a significant (50%-plus) reduction from baseline in abscess and inflammatory nodule count versus a placebo, with no advances in abscess or draining tunnel count.

Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase

**media[572458]**

PR NewswireSAN FRANCISCO and SUZHOU, China, March 18, 2025 SAN FRANCISCO and SUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innov

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (”œHUTCHMED”) (Nasdaq/AIM:”‹HCM; HKEX:”‹13) an

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program up

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires.

The S&P 500 edged up 0.6% on Monday, March 17, after a report showed retail sales recovered in February but fell short of expectations.